智通财经APP讯,复星医药(02196)公布,2025 年 4 月 29 日,公司控股企业苏州君明与河南复健、豫健生物、郑州航空港资本签订《合伙协议》,各方拟共同出资设立目标基金。目标基金将主要投资以中原地区为中心的医疗器械诊断、生命科学、创新药及其上下游产业链的创新型企业。
目标基金计划募集资金人民币25亿元,其中:苏州君明(作为 LP)拟现金出资人民币4.9亿元认缴目标基金中的等值财产份额。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.